1. Olsen & Goetzsche. Lancet 2000; 355:129-134 2. U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 344-346, 347-360 3. CNBCSS -2 . Ann Intern Med 2002; 137: 305-315 4. CNBCSS-1. J Natl Canc Inst 2000; 92:1490 5. Tabar L et al. Lancet 2003; 361: 1405-1410 6. Otto JS et al. Lancet 2003; 361: 1411-1417 7. Thorton E et al. BMJ 2003; 327:101-103 8. Zahl PH et al. BMJ 2004; 328:921-924 9. Elmore JG et al. Efficacy of Breast Cancer Screening in the Community According to Risk Level. J Natl Cancer Institute 2005 Jul 20; 97 (14): 1035-1043. 10. Zackrisson S et al. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 2006 Mar 25; 332:689-692 11. Jørgensen KJ, Gøtzsche PC.Content of invitations for publicly funded screening mammography . BMJ 2006 Mar 4; 332:538-541 12. Thorton H. Ramifications of screening for breast cancer. More debate and better information still needed . BMJ 2006 Mar 25; 332:728 13. Moss SM et al. for the Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006 Dec 9; 368:2053-2060 14. Qaseem A et al. for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening Mammography for Women 40 to 49 Years of Age: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med 2007 Apr 3; 146:511-515 15. Armstrong K et al. Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians. Ann Intern Med 2007 Apr 3; 146:516-526
|
|
